Galecto to Present at 2021 Cantor Virtual Global Healthcare Conference
BOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Galecto, a clinical stage biotechnology company focused on fibrosis and cancer treatments, announced that CEO Hans Schambye will present at an event on September 28, 2021, at 8:40 AM ET. The presentation will be accessible via a live audio webcast found on Galecto’s Investor website. Following the event, a replay will also be available. Galecto is advancing multiple Phase 2 clinical programs, including an inhaled modulator for idiopathic pulmonary fibrosis and an orally active inhibitor for myelofibrosis.
- None.
- None.
BOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that Hans Schambye, the Company’s Chief Executive Officer, will be presenting on Tuesday, September 28, 2021 at 8:40 AM ET and will be available for 1x1 meetings on the same date.
A live audio webcast will be available on the "Webcasts & Presentations" section of Galecto’s Investor website at https://ir.galecto.com/news-and-events/events. A replay of the presentation will be available on this same website following the event.
About Galecto
Galecto is a clinical stage company incorporated in the U.S. that is developing small molecule-based inhibitors of galectin-3 and LOXL2. Galecto has multiple ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 modulator (GB0139) in a phase 2b trial for the treatment of idiopathic pulmonary fibrosis (IPF); (ii) an orally active LOXL2 inhibitor (GB2064) in a phase 2 trial for the treatment of myelofibrosis; (iii) an orally active galectin-3 inhibitor (GB1211) in a phase 1b/2a trial in liver cirrhosis and expected to be evaluated in a phase 2 trial for the treatment of NSCLC in combination with an anti-PD1/-L1 product.
Galecto intends to use its website as a means of disclosing material non-public information. For regular updates about Galecto, visit www.galecto.com.
For more information, contact:
| Galecto, Inc. Hans Schambye, CEO Jon Freve, CFO +45 70 70 52 10 | |
| Investor Relations US Ashley R. Robinson arr@lifesciadvisors.com +1 617 430 7577 | Investor/Media Relations EU Sandya von der Weid svonderweid@lifesciadvisors.com +44 78 680 0538 |
FAQ
What will Hans Schambye discuss during the presentation on September 28, 2021?
How can I access the live audio webcast of Galecto's presentation?
What are the ongoing clinical programs for Galecto as of September 2021?
What is the date and time of Galecto's CEO presentation?
Where can I find updates about Galecto after the presentation?
